| First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia … G Martinelli, A Piciocchi, C Papayannidis, S Paolini, V Robustelli, ... Blood 130, 99, 2017 | 75 | 2017 |
| INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia G Martinelli, C Papayannidis, A Piciocchi, V Robustelli, S Soverini, ... Blood advances 6 (6), 1742-1753, 2022 | 50 | 2022 |
| Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T-cell progenitor acute lymphoblastic leukemia AGL Di Rorà, I Iacobucci, E Imbrogno, C Papayannidis, E Derenzini, ... Oncotarget 7 (33), 53377, 2016 | 41 | 2016 |
| Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia A Ghelli Luserna Di Rorà, N Beeharry, E Imbrogno, A Ferrari, V Robustelli, ... Journal of hematology & oncology 11, 1-18, 2018 | 40 | 2018 |
| Acute myeloid leukemia mutations: therapeutic implications C Papayannidis, C Sartor, G Marconi, MC Fontana, J Nanni, G Cristiano, ... International Journal of Molecular Sciences 20 (11), 2721, 2019 | 23 | 2019 |
| Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients E Zuffa, E Franchini, C Papayannidis, C Baldazzi, G Simonetti, N Testoni, ... Oncotarget 6 (31), 31284, 2015 | 23 | 2015 |
| Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia A Ghelli Luserna Di Rorà, M Bocconcelli, A Ferrari, C Terragna, S Bruno, ... Cancers 11 (11), 1654, 2019 | 22 | 2019 |
| Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment C Rizzari, MC Putti, A Colombini, S Casagranda, GM Ferrari, ... Hematology Reports 6 (3), 5554, 2014 | 20 | 2014 |
| Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia L Bertamini, J Nanni, G Marconi, M Abbenante, V Robustelli, F Bacci, ... BMC cancer 18, 1-5, 2018 | 18 | 2018 |
| An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia S Ragaini, S Wagner, G Marconi, S Parisi, C Sartor, J Nanni, G Cristiano, ... Blood Advances 6 (1), 87-99, 2022 | 15 | 2022 |
| A venetoclax and azacitidine bridge‐to‐transplant strategy for NPM1‐mutated acute myeloid leukaemia in molecular failure C Sartor, L Brunetti, E Audisio, A Cignetti, L Zannoni, G Cristiano, J Nanni, ... British Journal of Haematology 202 (3), 599-607, 2023 | 11 | 2023 |
| Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving … S Kayser, C Sartor, MR Luskin, J Webster, F Giglio, N Panitz, AM Brunner, ... Haematologica 107 (9), 2064, 2022 | 11 | 2022 |
| Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first‐line therapy with hypomethylating … A Candoni, D Lazzarotto, C Papayannidis, M Piccini, G Nadali, ... American Journal of Hematology 98 (4), E80-E83, 2023 | 9 | 2023 |
| Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant C Papayannidis, C Sartor, A Dominietto, E Zappone, M Arpinati, ... Hematological Oncology 39 (4), 580-583, 2021 | 9 | 2021 |
| Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile … C Sartor, C Papayannidis, MC Abbenante, I Iacobucci, A Broccoli, ... Hematology reports 5 (2), e7, 2013 | 8 | 2013 |
| Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating … C Papayannidis, J Nanni, G Cristiano, G Marconi, C Sartor, S Parisi, ... European Journal of Haematology 108 (6), 449-459, 2022 | 7 | 2022 |
| Long-term outcome after adoptive immunotherapy with natural killer cells: Alloreactive NK cell dose still matters S Parisi, L Ruggeri, E Dan, S Rizzi, B Sinigaglia, D Ocadlikova, ... Frontiers in Immunology 12, 804988, 2022 | 7 | 2022 |
| Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients PE Coppola, P Gaibani, C Sartor, S Ambretti, RE Lewis, C Sassi, ... Microorganisms 8 (12), 2055, 2020 | 7 | 2020 |
| Leukemia associated TP53 mutations in AML patients ARE strongly associated with complex karyotype and poor outcome A Ferrari, C Papayannidis, C Baldazzi, I Iacobucci, S Paolini, A Padella, ... Blood 124 (21), 2379, 2014 | 7 | 2014 |
| Next‐generation sequencing improves BCR‐ABL1 mutation detection in Philadelphia chromosome‐positive acute lymphoblastic leukaemia S Soverini, M Martelli, L Bavaro, C De Benedittis, C Papayannidis, ... British Journal of Haematology 193 (2), 271-279, 2021 | 6 | 2021 |
